GHTM

Global Health and Tropical Medicine

  • GHTM
    • About GHTM
    • Governance
    • Impact
    • Members
    • Scientific Advisory Board
    • Reports
      • GHTM
  • Research
    • Cross-cutting issues
      • Genomic Surveillance and Population Mobility
      • Antimicrobial Resistance and Drug Discovery
      • Host–Pathogen Interactions
      • Information for Health Development
      • Fair Research Partnerships
    • Research Groups
      • PPS – Population health, policies and services
      • PRIME – Pathogen resistance, infection and molecular epidemiology
      • VBD – Vector borne diseases
      • CTM – Clinical tropical medicine
    • Research in numbers
      • 2023
      • 2022
      • 2021
      • 2020
      • 2019
      • 2018
      • 2017
    • Projects
      • Ongoing Projects
      • Completed Projects
  • Outreach
    • Events
    • News
    • Policy Support & Community Outreach
  • Publications
    • 2024
    • 2023
    • 2022
    • 2021
    • 2020
    • 2019
    • 2018
    • 2017
    • 2016
    • 2015
  • Capacity Building
    • Education
      • Master Theses
      • PhD Theses
    • International
  • Infrastructures
    • BIOHUB & Available Software
    • BIOTROP Biobank
    • VIASEF & Insectaries
  • Networks & Partnerships
Home / Archives for Molnar J

In vitro cytotoxic activity of novel protoflavone analogs – selectivity towards a multidrug resistant cancer cell line.

  • Authors: Amaral L, Chang FR, Chuang DW, Danko B, Hunyadi A, Martins A, Molnar J, Wang HC, Wu YC
  • Journal: Anticancer Research
  • Link: http://www.ncbi.nlm.nih.gov/pubmed/?term=In+vitro+cytotoxic+activity+of+novel+protoflavone+analogs+%E2%80%93selectivity+towards+a+multidrug+resistant+cancer+cell+line

BACKGROUND:
Protoapigenone (PA), a natural flavonoid possessing an unusual p-quinol moiety on its B ring, is a prospective novel lead compound against cancer currently in development, together with WYC0209, a potent synthetic PA analog. Structure activity relationships (SAR) concerning different 1′-O-alkyl side-chains were also studied on two sets of derivatives.
Read More

Inhibitors of bacterial efflux pumps that also inhibit efflux pumps of cancer cells.

  • Authors: Amaral L, Armada A, Handzlik J, Kiec-Kononowicz K, Martins A, Molnar J, Spengler G
  • Journal: Anticancer Research
  • Link: http://www.ncbi.nlm.nih.gov/pubmed/22753759

Bacteria and cancer cells frequently increase their resistance to chemotherapeutics as a consequence of therapy. Whenever studied, refractory response to chemotherapy is due to the over-expression of efflux pumps that render the bacterium or cancer cell resistant not only to the agent used for therapy, but to many, if not all other agents as well.
Read More

Direct modification of bioactive phenothiazines by exposure to laser radiation.

  • Authors: Amaral L, Andrei IR, Boni M, Fanning S, Martins A, Militaru A, Molnar J, Nastasa V, Pascu A, Pascu ML, Smarandache A, Staicu A, Viveiros M
  • Journal: Recent Patents on Anti-Infective Drug Discovery
  • Link: http://www.ncbi.nlm.nih.gov/pubmed/?term=Direct+modification+of+bioactive+phenothiazines+by+exposure+to+laser+radiation.

Whereas exposure of combinations of a phenothiazine and bacterium to incoherent UV increases the activity of the phenothiazine, exposure of the phenothiazine alone does not yield an increase of its activity. Because the laser beam energy is greater than that produced by the incoherent UV sources, exposure of phenothiazines to specific lasers may yield molecules with altered activities over that of the unexposed parent.
Read More

  • « Previous Page
  • 1
  • …
  • 3
  • 4
  • 5

About GHTM

GHTM is a R&D Unit that brings together researchers with a track record in Tropical Medicine and International & Global Health. It aims at strengthening Portugal's role as a leading partner in the development and implementation of a global health research agenda. Our evidence-based interventions contribute to the promotion of equity in health and to improve the health of populations.

Contacts

Rua da Junqueira, 100
1349-008 Lisboa
Portugal

+351 213 652 600

  • Email
  • Facebook
  • LinkedIn
  • Twitter
  • YouTube

Funding

UID/04413/2025 - DOI: 10.54499/UID/04413/2025

UID/PRR/04413/2025 - DOI: 10.54499/UID/PRR/04413/2025

UID/PRR2/04413/2025 - DOI: 10.54499/UID/PRR2/04413/2025

  • Events
  • Research Groups
  • Cross-cutting issues
© Copyright 2026 IHMT-UNL All Rights Reserved.
  • Universidade Nova de Lisboa
  • Fundação para a Ciência e a Tecnologia

    UIDB/04413/2020
    UIDP/04413/2020

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.